Nxera Pharma receives $4.8m milestone payment
Nxera Pharma announced that it has received a USD 4.8 million (approximately JPY 689 million) milestone payment from Centessa Pharmaceuticals, a collaborator, as part of their research and development partnership. The payment is triggered by Centessa's acceptance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and subsequent commencement of a Phase 1 trial in healthy subjects for ORX142, a novel orexin 2 receptor (OX2R) agonist, the second in Centessa's orexin receptor agonist program. USD 1.8 million of the milestone is expected to be recognised as revenue in the second quarter of the fiscal year ending December 2025, with the remaining USD 3.0 million expected in the third quarter. ORX142 is a selective OX2R agonist developed by Centessa for specific neurological and neurodegenerative diseases.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sosei Group Corporation publishes news
Free account required • Unsubscribe anytime